Literature DB >> 25806240

Following the crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy.

Kalliopi Domvri1, Kaid Darwiche2, Paul Zarogoulidis1, Konstantinos Zarogoulidis1.   

Abstract

Entities:  

Year:  2013        PMID： 25806240      PMCID： PMC4367615          DOI： 10.3978/j.issn.2218-6751.2012.12.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  32 in total

1.  Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer.

Authors:  Joline S W Lind; Suresh Senan; Egbert F Smit
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

Review 2.  Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer.

Authors:  Vassiliki Papadimitrakopoulou
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

Review 3.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

Review 4.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Authors:  Helena Linardou; Issa J Dahabreh; Dimitra Kanaloupiti; Fotios Siannis; Dimitrios Bafaloukos; Paris Kosmidis; Christos A Papadimitriou; Samuel Murray
Journal:  Lancet Oncol       Date:  2008-09-17       Impact factor: 41.316

5.  Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.

Authors:  A Hallqvist; G Wagenius; H Rylander; O Brodin; E Holmberg; B Lödén; S-B Ewers; S Bergström; G Wichardt-Johansson; K Nilsson; L Ekberg; C Sederholm; J Nyman
Journal:  Lung Cancer       Date:  2010-06-11       Impact factor: 5.705

6.  Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Authors:  George R Blumenschein; Rebecca Paulus; Walter J Curran; Francisco Robert; Frank Fossella; Maria Werner-Wasik; Roy S Herbst; Philip O Doescher; Hak Choy; Ritsuko Komaki
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 7.  Targeting tumor neovasculature in non-small-cell lung cancer.

Authors:  Athanasios G Pallis; Konstantinos N Syrigos
Journal:  Crit Rev Oncol Hematol       Date:  2012-11-15       Impact factor: 6.312

Review 8.  Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Authors:  Rafael Rosell; Santiago Viteri; Miguel Angel Molina; Susana Benlloch; Miquel Taron
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

Review 9.  The potential role of mTOR inhibitors in non-small cell lung cancer.

Authors:  Cesare Gridelli; Paolo Maione; Antonio Rossi
Journal:  Oncologist       Date:  2008-02

10.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
View more
  15 in total

Review 1.  Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.

Authors:  Kalliopi Domvri; Paul Zarogoulidis; Kaid Darwiche; Robert F Browning; Qiang Li; J Francis Turner; Ioannis Kioumis; Dionysios Spyratos; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Lutz Freitag; Konstantinos Zarogoulidis
Journal:  J Cancer       Date:  2013-11-23       Impact factor: 4.207

2.  A new mode of ventilation for interventional pulmonology. A case with EBUS-TBNA and debulking.

Authors:  Paul Zarogoulidis; Haidong Huang; Chong Bai; Christoforos Kosmidis; Konstantinos Porpodis; Anastasios Kallianos; Lemonia Veletza; Georgia Trakada; Naim Benhassen; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-11-28

3.  Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.

Authors:  Paul Zarogoulidis; Panos Chinelis; Anastasia Athanasiadou; Theodora Tsiouda; Georgia Trakada; Anastasios Kallianos; Lemonia Veletza; Dimitris Hatzibougias; Electra Mihalopoulou; Eirini Goupou; Christoforos Kosmidis; Chrysanthi Sardeli; Haidong Huang; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-07-14

4.  Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.

Authors:  Paul Zarogoulidis; Aggeliki Rapti; Chrysanthi Sardeli; Panagiotis Chinelis; Anastasia Athanasiadou; Katerina Paraskevaidou; Anastasios Kallianos; Lemonia Veletza; Georgia Trakada; Wolfgang Hohenforst-Schmidt; Haidong Huang
Journal:  Respir Med Case Rep       Date:  2017-05-30

5.  "Liquid elbows" due to afatinib administration.

Authors:  Paul Zarogoulidis; Panos Chinelis; Anastasia Athanasiadou; Konstantinos Porpodis; Anastasios Kallianos; Aggeliki Rapti; Georgia Trakada; Lemonia Velentza; Haidong Huang; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-06-23

6.  Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.

Authors:  Paul Zarogoulidis; Haidong Huang; Theodora Tsiouda; Chrysa Sardeli; Georgia Trakada; Lemonia Veletza; Anastasios Kallianos; Christoforos Kosmidis; Aggeliki Rapti; Liana Papaemmanouil; Dimitrios Hatzibougias; Dimitrios Drougas; Chong Bai; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-10-26

7.  Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Kaid Darwiche; Thomas Vogl; Eugene P Goldberg; Haidong Huang; Michael Simoff; Qiang Li; Robert Browning; Francis J Turner; Patrick Le Pivert; Dionysios Spyratos; Konstantinos Zarogoulidis; Seyhan I Celikoglu; Firuz Celikoglu; Johannes Brachmann
Journal:  Drug Des Devel Ther       Date:  2013-07-18       Impact factor: 4.162

Review 8.  Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.

Authors:  Cristina Fernández-López; José Expósito-Hernández; Juan Pedro Arrebola-Moreno; Miguel Ángel Calleja-Hernández; Manuela Expósito-Ruíz; Rosa Guerrero-Tejada; Isabel Linares; José Cabeza-Barrera
Journal:  Cancer Med       Date:  2016-07-23       Impact factor: 4.452

9.  EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.

Authors:  Paul Zarogoulidis; Panos Chinelis; Christofors Efthymiou; Anastasia Athanasiadou; Vasilis Mpikos; George Papatsibas; Vasilis Papadopoulos; Elena Maragouli; Haidong Huang; Georgia Trakada; Anastasios Kallianos; Lemonia Veletza; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-05-30

10.  Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.

Authors:  Kalliopi Domvri; Konstantinos Zarogoulidis; Nikolaos Zogas; Paul Zarogoulidis; Savvas Petanidis; Konstantinos Porpodis; Efrosini Kioseoglou; Wolfgang Hohenforst-Schmidt
Journal:  J Cancer       Date:  2017-10-09       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.